Analysts have been eager to weigh in on the Healthcare sector with new ratings on Stoke Therapeutics (STOK) and Enanta Pharmaceuticals (ENTA).
Stoke Therapeutics (STOK)
Needham analyst Joseph Stringer assigned a Buy rating to Stoke Therapeutics today and set a price target of $65.00. The company’s shares closed last Wednesday at $58.20, close to its 52-week high of $64.54.
Stringer has an average return of 41.9% when recommending Stoke Therapeutics.
According to TipRanks.com, Stringer is ranked #2771 out of 7227 analysts.
Currently, the analyst consensus on Stoke Therapeutics is a Strong Buy with an average price target of $59.00.
See today’s analyst top recommended stocks >>
Enanta Pharmaceuticals (ENTA)
In a report released today, Jay Olson from Oppenheimer assigned a Hold rating to Enanta Pharmaceuticals, with a price target of $50.00. The company’s shares closed last Wednesday at $46.67.
According to TipRanks.com, Olson is a 4-star analyst with an average return of 4.5% and a 48.8% success rate. Olson covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Madrigal Pharmaceuticals, and Crispr Therapeutics AG.
Currently, the analyst consensus on Enanta Pharmaceuticals is a Hold with an average price target of $64.20, implying a 31.4% upside from current levels. In a report issued on January 7, RBC Capital also maintained a Hold rating on the stock with a $47.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.